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Abstract
Introduction: Amyloid beta (Aβ) oligomers are one of the most toxic structural forms
of the Aβ protein and are hypothesized to cause synaptotoxicity andmemory failure as
they build up in Alzheimer’s disease (AD) patients’ brain tissue. We previously demon-
strated that antagonists of the sigma-2 receptor complex effectively blockAβ oligomer
toxicity. CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of
the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly
volunteers. We tested CT1812’s effect on Aβ oligomer pathobiology in preclinical AD
models and evaluated CT1812’s impact on cerebrospinal fluid (CSF) protein biomark-
ers inmild tomoderateADpatients in a clinical trial (ClinicalTrials.govNCT02907567).
Methods:Experimentswere performed tomeasure the impact of CT1812 versus vehi-
cle on Aβ oligomer binding to synapses in vitro, to human AD patient post mortem
brain tissue ex vivo, and in living APPSwe/PS1dE9 transgenic mice in vivo. Additional
experiments were performed to measure the impact of CT1812 versus vehicle on Aβ
oligomer-induced deficits in membrane trafficking rate, synapse number, and protein
expression in mature hippocampal/cortical neurons in vitro. The impact of CT1812 on
cognitive function was measured in transgenic Thy1 huAPPSwe/Lnd+ and wild-type lit-
termates. A multicenter, double-blind, placebo-controlled parallel group trial was per-
formed to evaluate the safety, tolerability, and impact on protein biomarker expression
of CT1812 or placebo given once daily for 28 days to AD patients (Mini-Mental State
Examination 18–26). CSF protein expression was measured by liquid chromatography
with tandem mass spectrometry or enzyme-linked immunosorbent assay in samples
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coveryFoundation (20100501 [SC]), andby
CognitionTherapeutics.
drawn prior to dosing (Day 0) and at end of dosing (Day 28) and compared within each
patient and between pooled treated versus placebo-treated dosing groups.
Results: CT1812 significantly and dose-dependently displaced Aβ oligomers bound to
synaptic receptors in three independent preclinical models of AD, facilitated oligomer
clearance into the CSF, increased synaptic number and protein expression in neu-
rons, and improved cognitive performance in transgenic mice. CT1812 significantly
increased CSF concentrations of Aβ oligomers in AD patient CSF, reduced concentra-
tions of synaptic proteins and phosphorylated tau fragments, and reversed expression
of many AD-related proteins dysregulated in CSF.
Discussion: These preclinical studies demonstrate the novel disease-modifying mech-
anism of action of CT1812 against AD and Aβ oligomers. The clinical results are con-
sistent with preclinical data and provide evidence of target engagement and impact
on fundamental disease-related signaling pathways in AD patients, supporting further
development of CT1812.
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1 INTRODUCTION
Alzheimer’s disease (AD) afflicts sixmillion people in theUnited States,
yet disease-modifying therapies remain an unmet medical need. Inves-
tigational therapeutics are directed against a variety of potential
targets,1 but the amyloid hypothesis remains a compelling rationale for
AD drug development.2 More than 200 human mutations that cause
early-onset familial AD have been identified, almost all conferring a
single phenotype, increased amyloid beta (Aβ) protein concentration
or ratio.3,4 The only protective mutation that both significantly low-
ers AD incidence and also exhibits strong functional evidence of pro-
tection, A673T (the Icelandic mutation), also impacts the Aβ protein,5
resulting in significantly lowered binding affinity of Aβ oligomers at
synaptic receptors.6 Previous therapeutics have not effectively tar-
geted Aβ oligomers,7 one of the most toxic structural forms of the Aβ
protein.8 Whilemonomeric Aβ binds tomany receptors, the oligomeric
form of Aβ has been shown to bind specifically and saturably to a
single receptor site composed of LilRB2, Nogo receptor, and cellular
prion proteins9–11 on neuronal synapses, where they induce changes
consistent with a toxic disease-related ligand. After oligomer binding,
synaptic protein expression and the number of spines and synapses
are reduced,12–16 synaptic plasticity processes (long-term potential
and depression) are disrupted,14,17–25 and the process of newmemory
formation fails.2,8,10,11,26 Importantly, many preclinical studies suggest
that after removal or reduction of the toxic oligomer species, synap-
tic protein expression, synapse number, and behavioral deficits can
recover to normal levels.12,27
Here, we report the discovery and continued development of drug
candidate CT1812, a brain penetrant small molecule that targets
Aβ oligomers via a novel mechanism.26,28 The first selective sigma-2
receptor antagonist to reach clinical trials,29 CT1812 is shown here
to specifically displace Aβ oligomers bound to neuronal receptors.
The sigma-2 receptor complex plays a major role in cellular dam-
age response mechanisms, with its constituent proteins regulating
processes as diverse as autophagy, cholesterol synthesis and pro-
gesterone signaling, lipid membrane-bound protein trafficking, and
receptor stabilization at the cell surface.30–37 The sigma-2 receptor
complex has previously been shown to be a key regulator of Aβ
oligomer receptors.26,28 In the present study, we report evidence sup-
porting a hypothesized mechanism of CT1812 action: when CT1812
binds specifically to the sigma-2 receptor ligand binding site and
allostericallymodulates the sigma-2 receptor complex, it causes desta-
bilization of the neighboring Aβ oligomer receptor binding sites, result-
ing in displacement of Aβ oligomers from their receptors (in other
words, an increase in their “off rate”). This lowers Aβ oligomer affin-
ity for synaptic receptors, mimicking the effect of the protective
Icelandic mutation.6 This disruption of oligomer binding has previ-
ously been associated with an improvement in membrane traffick-
ing, neuronal surface expression of synaptic proteins, prevention of
spine loss, and improvement in cognitive deficits in animal models
of AD.26,28 The present study reports preclinical data demonstrat-
ing the novel mechanism of action of CT1812 in vitro and in vivo
in an AD transgenic mouse model, and preliminary cerebrospinal
fluid (CSF) biomarker data from the completed phase 1b/2a trial
(NCT02907567), supporting its disease-modifying mechanism in AD
patients.29
CT1812 is an investigational therapeutic that has not been
approved for any use by the US Food and Drug Administration.
The risk–benefit profile of CT1812 will be evaluated after adequate
placebo-controlled clinical trials have been completed.
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RESEARCH INCONTEXT
1. Systematic review: The authors engage in routine
surveillance of relevant publications via PubMed and
direct review of new issues of journals that publish
research related to Alzheimer’s disease (AD) or any
mechanisms and research techniques used by the authors
of this article. The articles are extensively referenced
throughout.
2. Interpretation: These results are consistent with pre-
viously published preclinical evidence and demonstrate
CT1812’s target engagement and fundamental impact on
disease-related signaling pathways in patients with AD.
3. Future directions: These results support further develop-
mentofCT1812,which is currently inmultiple phase2 tri-
als in patients with AD.
2 RESULTS
2.1 CT1812 displaces and prevents Aβ oligomer
binding
Previously published studies that described unbiased proprietary
library screening to identify compounds that block Aβ oligomer-
induced toxicity of intracellular lipid membrane trafficking rates
revealed compound potency correlated with sigma-2 receptor
affinity.26,28 Medicinal chemistry optimization resulted in the design
of CT1812. CT1812 binds sigma-2 receptors with high affinity
(Figure 1A, Ki = 8.5 nM), sigma-1 receptors with low affinity
(Ki = 63 nM), and is 100-fold selective for interacting with sigma-
2 receptors versus 72 other drug targets (Cerep/Eurofins; Figure S1 in
supporting information). CT1812 effectively prevented (EC50 = 6.7
μM) and reversed (EC50 = 0.36 μM) synthetic Aβ oligomer-induced
membrane trafficking deficits in vitro in primary hippocampal/cortical
cultures (21DIV, Figure 1B) and prevented human AD patient brain-
derived oligomer-induced trafficking deficits (Figure 1C). CT1812
prevented binding of Aβ oligomers to synaptic receptor sites on
neurons (Aβ oligomer binding Kd = 0.43 μM, plus CT1812 = 1.12 μM,
Figure 2A, B, D), and also displaced already-bound Aβ oligomers (Aβ
oligomer binding Kd = 0.61 μM, plus CT1812 = 1.16 μM, Figure 2C,
E). CT1812 did not block the formation of Aβ oligomers or disrupt
their formation at concentrations up to 20μM (Figure S2 in supporting
information), suggesting that its ability to stop Aβ oligomer binding
and trafficking deficits results from CT1812 direct binding to sigma-2
receptors.
2.2 CT1812 restores disease-related protein
expression and synapse number in vitro
Aβ oligomers induce reversible spine retraction in vitro38 and cause a
corresponding loss of synapses and synaptic proteins.13,26 The effect
ofCT1812-induceddisplacement ofAβoligomers onoligomer-induced
spine and synapse loss in cultured rat neurons was investigated using
the cytoskeleton binding protein drebrin (expressed postsynaptically)
as a marker of synapse number. Addition of Aβ oligomers to neu-
ronal cultures for 3 hours caused a significant loss (mean ± standard
error of the mean 12.8% ± 2.6%, P < 0.01, two-tailed Student’s t
test, Figure 2F top, G) of drebrin-immunoreactive synaptic puncta
F IGURE 1 CT1812 is a selective sigma-2 receptor ligand that prevents and treats amyloid beta (Aβ) oligomer-inducedmembrane trafficking
deficits. A, CT1812 binds sigma-2 receptors with a 8.5 nMKd and sigma-1 receptors with a 63 nMKd asmeasured in radioligand displacement
studies (n= 2; means± standard deviation [SD]). B, Effects of synthetic Aβ oligomers on vesicle trafficking in primary cultures of neurons and glia.
Quantification is shown of the amount of formazanwithin intracellular vesicles in Aβ oligomer-treated (red dot) or vehicle-treated (blue square)
conditions, and the dose-dependent restoration of trafficking rate to normal vehicle-treated values after CT1812 addition 1 hour before addition
of Aβ oligomers (gray squares, EC50= 6.7 μM, n= 11 experiments) or 1 hour after addition of Aβ oligomers (black squares, EC50= 0.36 μM,
n= 12 experiments). Vesicle trafficking was assayed 24 hours after addition of Aβ oligomers (1.75 μM, total peptide; means± standard error of the
mean). N represents the number of replicate experiments from separate cell culture preparations. C, Human Alzheimer’s disease brain derived Aβ
oligomers (1-hour treatment) caused a 27± 11% (SD; P< 0.001, n= 3) decrease in trafficking rate in cultured neurons and glia. Pretreatment of cul-
tures for 1 hour with 15 μMCT1812 before addition of human derived Aβ oligomers blocked the trafficking deficits (P< 0.001 for Aβ oligomers vs.
Aβ oligomers+CT1812, analysis of variancewith Tukey’s post hoc test, n=3 experiments). Each point represents results fromquadruple replicates
fromAβ oligomer preparations isolated from three separate donor brains with themean of all the points represented by the horizontal lines
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F IGURE 2 CT1812 prevents amyloid beta (Aβ) oligomer binding to and displaces bound oligomers from neuronal receptors, leading to
restoration of synaptic density and protein expression in culturedmouse neurons. A, Aβ oligomers (750 nM,> 80% of Kd) bind specifically and
saturably to a single receptor site on some, but not all, neurons in mature (> 21DIV) primary hippocampal and cortical neuronal cultures. B,
CT1812 [10 uM] prevents Aβ binding by 59± 8% (standard error of themean [SEM]) when added 1 hour prior to addition of Aβ oligomers. C,
CT1812 [10 uM] displaces Aβ oligomer binding by 42± 9% (SEM)when added 1 hour after addition of Aβ oligomers. Scale bar= 20microns. D,
CT1812 prevents binding andmore than doubles the Kd of oligomer binding, from 430 nM (at 0 μMCT1812) to 1120 nM (at 10 μMCT1812; n= 6;
means± SEM). E, CT1812 displaces binding and nearly doubles the Kd of oligomer binding, from 610 nM (at 0 μMCT1812) to 1160 nM (for 10 μM
CT1812; n= 6; means± SEM). F, top, Aβ oligomers bind to receptors at neuronal synapses (red, 6E10 immunodetection), resulting in a significant
loss of synapses (green, drebrin immunodetection, 12.8± 2.6% [SEM] decrease in synapse density, P< 0.01 vs. vehicle-treated, Student t test [G];
the blue square represents synapse density in vehicle-treated neurons). F, bottom,CT1812 displaces bound Aβ oligomers and restores synaptic
numbers to normal in a dose-dependent manner. Scale bar= 5microns. G, CT1812 restores synapse number to normal whether added before
(prevention, EC50= 68 nM) or after (treatment, EC50= 127 nM) Aβ oligomers (*P< 0.5 vs. Aβ oligomers alone for both conditions, Student’s t
test, means± SEM). Treatment with CT1812 restores synaptic protein expression in cultured rat neurons. H, Neurogranin is expressed at high
levels in postsynaptic dendrites and synapses in a subset of neurons in primary hippocampal/cortical cultures. I, Addition of Aβ oligomers (0.75 μM,
24 hours) causes a 28% loss of neurons expressing high levels of neurogranin (P= 0.014). J, Treatment with 4.8 μMCT1812 1 hour after addition of
Aβ oligomers restores the expression of neurogranin to normal levels (Aβ oligomers vs. Aβ oligomers+CT1812 P= 0.031, vehicle vs. Aβ oligomers
+CT1812, n.s., analysis of variance [ANOVA] with Tukey’s post hoc test, n= 20). K, Synaptotagmin-1 is expressed in presynaptic terminals. L,
Addition of Aβ oligomers (3.5 μM, 48 hours) cause a 37% loss of synaptotagmin-1 presynaptic terminals in primary hippocampal/cortical cultures
(P= 0.0068,N= 24). M, Treatment with 4.8 μMCT1812 1 hour after addition of Aβ oligomers blocks these losses and restores expression of
synaptotagmin-1 levels (vehicle vs. Aβ oligomers+CT1812, n.s). H–M, ANOVAwith Tukey’s post hoc test, n= 20. For all cell culture experiments, n
represents the number of replicate experiments from separate cell culture preparations, and data points represent means± SD or SEM as noted
per neuron compared to vehicle treatment. This is similar to the
degree of synapse loss seen using ultrastructural stereology meth-
ods in post mortem hippocampus from humans diagnosed with mild
cognitive impairment.39 CT1812 prevented oligomer-induced synapse
loss in a dose-dependent manner (EC50 = 68 nM, P < 0.05, paired,
Student’s t test of treated vs. vehicle, Figure 2F bottom, G). Further-
more, addition of CT1812 to cultures 1 hour after the addition of Aβ
oligomers resulted in a concentration-dependent increase of synaptic
number to normal levels (EC50 = 127 nM, Figure 2G). Examination of
synaptic protein expression corroborated these results. Neurogranin is
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F IGURE 3 CT1812 treatment displaces amyloid beta (Aβ)
oligomers frommouse hippocampal receptors and post mortem
Alzheimer’s disease human patient tissue and facilitates their
clearance into cerebrospinal fluid (CSF). A, B, Microimmunoelectrodes
(MIE) coated with oligomer-specific antibody A11 (A) or mAβ40
antibody HJ2 (B) in 12-month-old transgenic hAPP/PS1mice detect
soluble Aβ in the hippocampal interstitial fluid (ISF). A, After
intravenous injection of 0.3 or 3mg/kg CT1812 (vertical dashed line),
soluble Aβ oligomers are significantly elevated in hippocampal ISF in
CT1812-treatedmice (n= 7) compared to vehicle-treatedmice (n= 4,
means± standard error of themean [SEM]; *** P< 0.001, ****
P< 0.0001, two-way analysis of variance [ANOVA] with Sidak’s post
hoc test for effect of drug vs. vehicle). B, CT1812 treatment does not
cause a change in total Aβ levels in the hippocampus (n= 5) compared
to vehicle treatment (n= 4, means± SEM). C–E, Aβ oligomers
displaced from post mortem brain tissue sections from 8AD patients
were quantified by enzyme-linked immunosorbent assay (ELISA; D)
and native western blots (C [representative individual patient], E), and
show the expected dose-dependent increase in concentration in
CT1812-treated compared to the vehicle-treated condition. For
western blots, the sum of the intensity of discrete Aβ protein bands at
22, 33, 43, 48, and 85 Kdwas quantified for each donor tissue section
(C). In (D) and (E), values for Aβmeasured by ELISA for each brain
tissue section and for intensity of western blot bands for each brain
tissue section normalized to vehicle-treated controls (dashed line)
expressed in dendrites and postsynaptic terminals (Figure 2H), while
synaptotagmin-1 is expressed in presynaptic terminals (Figure 2K) of
mature primary hippocampal/cortical neurons in vitro. Aβ oligomer
treatment led to a 28% loss of neurons expressing high levels of neu-
rogranin (Figure 2I) and a 37% loss of synaptotagmin-1 presynaptic
terminals (Figure 2L). Treatment with CT1812 blocked this loss and
restored expression of both proteins to control levels (Figure 2J, M).
This suggests that CT1812-mediated displacement of Aβ oligomers
from neuronal synapses stops both downstream oligomer-induced
synaptic protein downregulation and synapse loss, facilitating synaptic
recovery from toxic oligomer insult.
2.3 CT1812 displaces Aβ oligomers and facilitates
clearance into CSF in vivo and in AD patient brain
tissue
To confirm the displacement of Aβ oligomers from cells observed
in vitro using an in vivo mouse model of AD, we adapted a novel
microimmunoelectrode (MIE) technology previously used to detect
rapid kinetic changes in total Aβ concentration in brain interstitial
fluid (ISF)40 (Figure S3A-E in supporting information). Using elec-
trodes coated with the oligomer-specific antibody A1141 placed in the
hippocampus, Aβ oligomers were measured in ISF of 12-month-old
APPSwe/PS1dE9 transgenic mice.
42 A single dose of CT1812 (0.3 μM,
or 3.0 μM i.v.) resulted in a rapid and significant increase in Aβ oligomer
levels in hippocampal ISF relative to predose baseline (Figure 3A, verti-
cal dashed line, see Figure S3F). In contrast, no increase was observed
in the ISF of vehicle-treated transgenic mice. The rapid elevation of Aβ
oligomers after drug administration declined to baseline levels within
the timeframe of the recording (120 minutes). In contrast, total Aβ
levels (primarily monomer) in the hippocampal ISF were not affected
by the administration of CT1812 (Figure 3B), thus CT1812 selectively
from the same donor are shown, with themean of all the points
represented by the horizontal lines (*P< 0.05, ANOVAwith Tukey’s
post hoc test for each treatment vs. vehicle treated controls). F
(representative individual patient), G, H, Aβ oligomers (red) located in
a 2 μMhalo surrounding compact thioflavin-S positive plaques (green)
are displaced from frozen post mortem human AD brain tissue sections
(N= 5 patients) by CT1812 in a dose-dependent manner normalized
to vehicle treated brain sections (dashed line) from the same individual
with themean of all the points represented by the horizontal lines
(*P< 0.05, ANOVAwith Tukey’s post hoc test for each
CT1812-treated vs. vehicle-treated controls). H, Aβ intensity within
plaques does not change. Scale bar= 20 μM. I, J,
Microimmunoelectrodes coatedwith oligomer-specific antibody A11
(I) or pan-Aβ antibody HJ2 (J) in 12-month-old transgenic hAPP/PS1
mice detect soluble Aβ in the lateral ventricle CSF. I, After intravenous
injection of 0.3 (n= 7) or 3 (n= 5) mg/kg CT1812 (vertical dashed line),
soluble Aβ oligomers are significantly elevated in lateral ventricle CSF
compared to vehicle-treatedmice (n= 5, means± SEM). J, CT1812
treatment (n= 5) did not cause a change in Aβmonomer levels in the
CSF compared to vehicle treatment (n= 4means± SEM). ***
P< 0.001, **** P< 0.0001, two-way ANOVA Sidak’s post hoc test for
effect of drug vs. vehicle
6 IZZO ET AL.
reduces Aβ oligomer extracellular concentrations without affecting Aβ
monomer levels.
To assess whether CT1812 displacement of Aβ oligomers in AD
model systems in vitro and in vivo may also occur in AD patients, we
conducted ex vivo binding experiments in 10 μM-thick post mortem
neocortical tissue sections obtained from patients with AD (Clinical
Dementia Rating [CDR] = 3, n = 8 patients, Figure 3C-E). After incu-
bation of adjacent sections in identical volumes containing increas-
ing concentrations of CT1812 or vehicle, the supernate was removed
and the levels of Aβ displaced from the tissue sections quantified
by enzyme-linked immunosorbent assay (ELISA); the Aβ remaining in
the tissue sections was quantified via immunofluorescent microscopy.
Analysis of the displaced material by ELISA for total Aβ showed that
ascending concentrations of CT1812 increased the amount of Aβ
released from the human brain tissue (Figure 3D): non-denaturing
western blots confirmed this material to be Aβ oligomers (Figure 3C,
E, Figure S4 in supporting information). Additionally, CT1812 induced
a concentration-dependent decrease in Aβ oligomer immunofluores-
cence intensity in the 2 μm region containing high concentrations of
oligomers surrounding dense, thioflavin-S labeled plaque cores43,44
(Figure 3F, G) with similar but not statistically significant changes
occurring within the plaque itself (Figure 3H). These results demon-
strate that CT1812 displaces prebound Aβ oligomers from AD patient
brain tissue.
Finally, the fate of Aβ oligomers displaced by CT1812 was deter-
mined by placing the A11-coated MIE in the lateral ventricle of trans-
genic APPSwe/PS1dE9 mice to measure Aβ oligomers in the CSF. A
significant, dose-dependent rise in Aβ oligomer levels was detected
in CSF after drug administration (Figure 3I) and remained elevated
for up to 2 hours, suggesting that displacement of Aβ oligomers in
the brain may lead to increased clearance into the CSF. In contrast,
Aβ monomer levels in the CSF were not affected by administration
of CT1812 (Figure 3J), indicating that CT1812 selectively facilitates
clearance of oligomers, but notmonomers, from the brain into the CSF.
2.4 CT1812 improves cognitive performance in
transgenic mice
To assess whether this evidence of synapse preservation by CT1812
was associated with functional behavioral improvement, we evaluated
changes in cognitive deficits in an aged transgenic mouse model of
AD.26,45,46 Transgenic Thy1 huAPPSwe/Lnd+ male mice, aged 3.5 to 4.5
months, or wild-type (WT) littermates, were administered vehicle or
CT1812 10 mg/kg once daily by oral gavage for 9 to 10 weeks (n = 12
for each group except for the transgenic CT1812-treated group, which
was n = 13). Treatment of WT mice with CT1812 did not significantly
alter motor behavior and did not change cognitive performance com-
pared to that of WT vehicle-treated animals. As expected, significant
deficits in transgenic vehicle-treated animals compared toWT vehicle-
treated animals were observed in the Activity Chamber test measur-
ing exploration, the Y maze measuring spatial working memory, and
the Fear Conditioning assays measuring aversive associative learning
andmemory. Significant improvements in spatial learning andmemory
wereobserved in transgenic animals treatedwithCT1812compared to
those treated with vehicle in the Water Maze (Figure 4A), the Y-Maze
(Figure 4B), and in contextual fear conditioning (Figure 4C). In addition
to improving spatial learning and memory, significant improvements
were observed in hyperactivity as assessed via the Activity Chamber
assay, and cue-dependent learning andmemory as assessed in the Fear
Conditioning assay. InWTmice, CT1812 had no effect on performance
in any of the cognitive tests (Figure 4A-C).
Previous studies of eight other sigma-2 receptor antagonists closely
related to CT1812 in Thy1 huAPPSwe/Lnd+ mice treated daily for
4 weeks to 6 months indicated that behavioral improvements were
observed as long as brain concentrations of drug were above a the-
oretical 80% receptor occupancy threshold concentration,26 but that
plaque number and Aβ monomer concentration (measured by ELISA)
did not change. PK measurements of brain concentrations of CT1812
after treatment of Thy1 huAPPSwe/Lnd+ mice with 10 mg/kg p.o. for 9
to 10 weeks confirmed that this estimated 80% receptor occupancy
level was achieved (Figure 4D, brain concentration 24 hours after last
dose= 19.9 ng/mL, 84.4% receptor occupancy, greater than four times
the sigma-2 receptor Ki value). Taken together, these studies indicate
that threshold brain concentrations of CT1812 effectively improved
cognitive deficits found in the huAPPSwe/Lnd+ mousemodel of AD.
2.5 Clinical biomarker evidence of
CT1812-mediated synapse protection and disease
modification
After completion of first-in-man clinical studies (NCT0257099729),
CT1812 was advanced into clinical trials in AD patients. Mild-to-
moderate AD patients withMini-Mental State Exam (MMSE) scores of
18 to26were randomized to receive oneof three doses ofCT1812 (90,
280, 560 mg) or placebo once daily for 28 days (N = 19, 4–5/group)
in a double-blind phase 1b/2a clinical trial to determine safety and
tolerability (trial COG0102, for full description, see clinicaltrials.gov
NCT02907567). The randomized patients, 10 male and 9 female, had
a mean age of 70.2 years (standard deviation [SD] 9.2) and body mass
indexof 24.75kg/m2 (SD2.73). CSF concentrations at baseline andDay
28 confirmed no presence of CT1812 in the placebo group or at base-
line in any dose group. Day 28 mean CSF concentrations of CT1812
rose in a dose-dependent manner (1.15 ng/mL [SD 0.53] in the 90 mg
treatment group, 2.84 ng/mL [SD 0.69] in the 280mg treatment group,
and 4.96 [SD 8.49] in the 560 mg treatment group). As expected in a
study of limited treatment duration, change in exploratory measures
of cognitive function from baseline was similar in CT1812-treated and
placebo groups. CSF samples collected from each patient at baseline
and at the end of study were used for protein measurements using
targeted (i.e., ELISA, western blot, liquid chromatography with tandem
mass spectrometry [LC-MS/MS) and nontargeted (i.e., unbiased LC-
MS/MSproteomics)methods;missing samples andvariable samplevol-
umes reduced the number of matched baseline and day 28 patient CSF
samples available for subsequent analysis.
Protein gel electrophoresis (western blot) was used to measure Aβ
oligomer concentration in CSF samples from each patient taken at Day
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F IGURE 4 Treatment with CT1812 improves learning andmemory deficits in transgenic Alzheimer’s mice. A, Transgenic Thy-1
huAPPSwe/Ldn+malemice treated with CT1812 (Tg+CT1812) learn theMorris water maze task significantly better than do transgenic
vehicle-treatedmice (Tg+ vehicle; P= 0.016, two-way repeatedmeasures analysis of variance, Bonferroni post hoc *P< 0.5; mean± standard
error of themean). CT1812 treatment does not affect non-transgenic animal performance (nTg+CT1812). B, Transgenic mice treated with
CT1812 remember previous arms entered in the Ymaze task significantly better (P= 0.013, Student’s t test) than chance (dashed line), but
transgenic vehicle-treated animals do not (nTg+ vehicle, 62.7± standard deviation [SD] 12.2%; Tg+ vehicle, 56.1± SD 9.2%; Tg+CT1812, 58.5±
SD 9.4%; nTg+CT1812, 65.3± SD 6.0%). C, Transgenic mice show deficits in the Contextual Fear Conditioning test (P= 0.037, Student’s t test),
while transgenic and nontransgenic mice treated with CT1812 do not (nTg+ vehicle, 52.5± SD 5.4%; Tg+ vehicle, 37.9± SD 6.4%; Tg+CT1812,
44.6± SD 6.5%; nTg+CT1812, 50.9± SD 5.1%). Each data point in (B) and (C) represents an individual mouse with themean of all the points
represented by the horizontal lines. D, Plasma and brain concentration of CT1812 after a single p.o. dose of 10mg/kg (n= 3mice per time point,
mean± SD)
0 and 28 and percent change for each patient was calculated. Due
to the small number of AD patients in each dosing group, CT1812
dose groups were pooled for comparisons to placebo. After 28 days of
treatment, CSF Aβ oligomer concentration (n = 3) in placebo-treated
patients trended lower from levels at their own baseline, while levels in
CT1812-treated patients (n = 10) increased significantly compared to
placebo-treated patients (Figure 5A and Figure S5 in supporting infor-
mation). This finding is consistent with preclinical studies indicating
that CT1812 displaces and clears toxic Aβ oligomers from the brain
into CSF (Figure 3I) and provides supporting evidence of clinical tar-
get engagement. In contrast, Aβ40 and 42 monomer levels measured
with ELISA were not different between Day 0 and Day 28, or between
treatment groups in this trial (Figure S5B, C).
The concentrations of several synaptic and axonal proteins are ele-
vated in CSF of AD patients compared to age-matched cognitively nor-
mal individuals as a result of central nervous system synaptic damage
due to the disease;47–51 some markers exhibit greater sensitivity to
disease-related changes than do others. We measured concentrations
of synaptic and axonal proteins inCSF samples fromADpatients in trial
COG0102 using ELISA (neurogranin and neurofilament light [NfL]) or
targetedLC-MS/MS (synaptotagmin-1, SNAP-25). At 28days,CSF con-
centrations of neurogranin and SYT-1 decreased in CT1812-treated
AD patients relative to placebo-treated AD patients CSF (Figure 5B,
neurogranin, n = 5 placebo, 11 treated; P = 0.050 analysis of covari-
ance; Figure5C, synaptotagmin-1,n=4placebo, 9 treated; F1,12=8.8,
P = 0.011, linear mixed model), consistent with preclinical evidence
of CT1812-mediated facilitation of synaptic recovery from insult with
toxic Aβ oligomers. CSF concentrations of NfL and SNAP-25 did not
change to a significant degree in CT1812-treated AD patients versus
placebo (Figure S5D, G).
Data from unbiased LC-MS/MS proteomics measurements of CSF
were evaluated for effects on synaptic proteins (Figure 5D). Of
the 3160 proteins detected in the CSF of this patient cohort,
the abundance of 315 proteins was significantly different between
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F IGURE 5 CT1812 treatment significantly impacts cerebrospinal fluid (CSF) biomarkers of target engagement and disease-related biology.
Protein concentrations in CSF samples fromAlzheimer’s disease (AD) patients in a 28-day phase 1b/2a clinical trial of CT1812 vs. placebowere
measured via enzyme-linked immunosorbent assay (ELISA), liquid chromatography tandemmass spectrometry (LC-MS/MS), or gel
electrophoresis. A, After 28 days the concentration of amyloid beta (Aβ) oligomersmeasured via western blot in CT1812-treated AD patient CSF
increases compared to the patient’s own baseline and vs. placebo (P= 0.014, Student’s t test, n= 3 placebo, 10 CT1812-treated), providing
supporting evidence of clinical target engagement. At day 28 of the study, the concentration of synaptic damage proteins neurogranin (B,
measured by ELISA) and synaptotagmin-1 (C, measured by LC-MS/MS) decreases compared to the patient’s own baseline and vs. placebo
(P= 0.050 analysis of covariance, n= 5 placebo, 11 CT1812-treated; and F1,12= 8.8, P= 0.011, n= 4 placebo, 9 CT1812-treated, respectively)
providing evidence of a positive effect on synapses in patients with AD. A, B, and C, Data from individual patients are displayedwith the treatment
groupmean represented by the horizontal lines. These changes are corroborated (D) by significant expression changes (P< 0.05) in multiple
synaptic proteome proteins in the CSFmeasured by unbiased LC-MS/MS in AD patients treated for 28 days with CT1812 vs. placebo. E, CSF
proteomics identifies a subset of proteins significantly alteredwith CT1812 that have been reported to be significantly regulated in AD.92 Data are
expressed asmean% change in protein concentration in CSF fromCT1812 treated (n= 11) vs. placebo (n= 4; blue) and AD vs. control to illustrate
how these proteins are altered in AD relative to cognitively normal age-matched controls. All analytes shown are significantly regulated (P< 0.05)
in AD patients vs. control53 and in the present study. F, After 28 days of treatment, the abundance of six tau phosphorylation peptides decreased
by 30% (the threshold for noise distribution), or more after treatment with CT1812 compared to placebo (T52, T205, S262, S263, S285, S305)
while one site increasedmore than 30% (S191), but the concentration of unphosphorylated tau did not change, providing evidence of CT1812
impact on pathological disease signaling. Colored bars represent amino acid sites within tau that are phosphorylated by GSK3βwith priming (blue
bars) or without priming (green bars)93,94
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CT1812- and placebo-treated patients (analysis of variance [ANOVA]
followed by Fisher’s least significant difference [LSD]; P < 0.05).
Pathway analysis using three independent bioinformatics platforms
(IPA Canonical Pathway [v51963813], Metacore [v19.4 build 69900],
STRING [v11]) indicates that CT1812 significantly (P < 0.05) impacts
synaptic-related pathways including N-methyl-D-aspartate receptor
trafficking, glycogen kinase synthase kinase-3β (GSK3β), and Wnt
signaling, as well as cytoskeletal reorganization. Given the loss of
synapses in AD patients along with the preclinical evidence that
CT1812 rescues synapse number, we queried which proteins in the
synaptic proteome52 were altered by CT1812 treatment. Twenty-five
proteins in the synaptic proteome52 were identified to be differentially
expressed (ANOVA followed by Fisher’s LSD; P < 0.05) in CT1812-
compared to placebo-treated patient CSF. To understand the functions
of these proteins with respect to specific synaptic function in more
detail, network analysis was performed. The highest scoring network,
Cell Morphology, Cellular Assembly and Organization, Cellular Devel-
opment, comprised 14 out of 25 of the synaptic proteins, a significantly
greater number than expected by random chance (Figure S6A in sup-
porting information, IPA Score = 26; P < 1 × 10–25). This indicates
that these proteins may play a role in dendritic branching, cytoskele-
tal remodeling, and neurotransmission (Figure S6B). This provides evi-
dence supporting CT1812’s positive effect on synapses in patients
with AD.
Out of 520 CSF proteins significantly altered in AD patients versus
age-matched controls (P<0.05) in a recent study,53 334were detected
in theCOG0102CSF proteomics dataset. Of those 334 proteins, a sub-
set of 20 moved in the opposite direction (i.e., reversed AD-related
changes) and were also significantly different in CT1812-treated com-
pared to placebo (Figure 5E). Several of these proteins are involved in
key biological pathways known to be disrupted in AD, including choles-
terol transport (apolipoprotein A2 [APOA2]), oxidative stress (cerulo-
plasmin [CP]), complement (complement C1r subcomponent-like pro-
tein [C1RL]), and synaptic transmission (14-3-3 protein beta/alpha
[YWHAZ]). This provides supporting evidence for a broad improve-
ment of disease-related signaling by CT1812 in patients with AD.
One of the hallmarks of AD is hyperphosphorylated tau protein,
which comprises neurofibrillary tangles (NFTs).54–58 We evaluated AD
patient CSF for concentrations of unphosphorylated and phospho-
rylated tau protein fragments taken at baseline and after 28 days
of CT1812 or placebo treatment via LC-MS/MS (Figure 5F); phos-
phorylated peptide fragments representing 33 distinct phosphoryla-
tion sites on tau were detected. The abundance of six phosphory-
lation sites decreased by 30% or more (Figure 5F)59,60 after treat-
mentwith CT1812 compared to placebowhile one site increasedmore
than 30% (the threshold for noise distribution61), but the concentra-
tion of unphosphorylated tau did not change. In agreement with these
results, ELISA measurements of the change from baseline of phospho
tau (p-tau) (181) and total tau (t-tau) was similar in CT1812-treated
and placebo groups (Figure S5E, F). Additionally, LC-MS/MS measure-
ments of concentrations of kinases that phosphorylate tau, such as
GSK3β, trended lower by 25% in CT1812-treated patients (not sig-
nificantly different from placebo-treated patients, P = 0.098). These
results suggest that CT1812may act upstreamof tau kinases to reduce
their concentration and resulting activity, while having no impact on
tau expression or regulation. To identify phosphorylation sites within
tau that might covary in abundance in response to CT1812 treat-
ment, correlation analyses were performed and a heatmap was gen-
erated. The abundance of 21 pairs of p-tau sites was found to be sig-
nificantly correlated with one another (Figure S7 in supporting infor-
mation), supporting the hypothesis that CT1812 may act upstream
of tau kinases/phosphatase to impact tau phosphorylation at specific
amino acid sites. Taken together, these clinical biomarker data support
a potential therapeutic impact of CT1812 in patients with AD.
3 DISCUSSION
3.1 CT1812 displaces Aβ oligomers in several
preclinical models of AD
The Aβ oligomer hypothesis remains a compelling rationale for AD
drugdevelopment programs.2 Supporting evidence for this comes from
the genetic determinants of autosomal dominant AD and AD compli-
cating Down syndrome,62 the protective effect of the Icelandic muta-
tion of the amyloid precursor protein5,6 animal data indicating the
toxic effects of Aβ oligomer species on synaptic function8,63 and its
reversibility,27 and the observation that Aβ accumulation alone in cog-
nitively and clinically normal individuals predicts symptomatic ADwith
high likelihood.64 Drug development programs targeting Aβ include
active and passive Aβ immunotherapeutics7 and secretase inhibitors
that decrease Aβ peptide generation,65 but none effectively or selec-
tively target Aβ oligomers.
The current study demonstrates that CT1812 displaces Aβ
oligomers from neurons with three independent approaches: in vitro
cell culture, in vivo rodent studies (including two different mouse
models of AD), and ex vivo human brain CSF and tissue. In cultured rat
brain cells in vitro, CT1812 shifted the binding of exogenously applied,
synthetic Aβ oligomers to lower affinity whether added before or
after oligomers. Importantly, CT1812-mediated reduction of oligomer
affinity phenocopies or mimics the effect of the AD’s protective
Icelandicmutation on oligomer affinity,6 and is the only drug candidate
currently in development reported to do so. This is significant because
drug candidates with the same mechanism as protective variants
are expected to have a higher success rate in the clinic.66 CT1812
treatment for 1 hour did not decrease the intensity of pre-bound Aβ
oligomers as completely as it did when added to cultures prior to
the oligomers. It is possible that longer treatment with CT1812 can
achieve a greater level of displacement. However, incubation with Aβ
oligomers for longer times results in internalization of a portion of the
Aβ oligomer labeling,26 complicating quantification of the compound
treatment. Nonetheless, our results demonstrate that CT1812 both
displaces already-bound Aβ oligomers and prevents the binding of Aβ
oligomers to neuronal synaptic receptors; displaced oligomers will
not re-bind as long as CT1812 remains present. Thus, CT1812 will
likely continue to exert its effect as concentrations of oligomers rise
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throughout the course of AD. In separate biochemical assays using
an oligomer-specific ELISA, CT1812 does not interact directly with
oligomers and did not disrupt preformed oligomers or block oligomer
formation (Figure S2). In post mortem human AD brain tissue sections,
CT1812 caused a concentration-dependent increase in Aβ displaced
from the tissue as measured by Aβ ELISA, as well as a concentration-
dependent increase in several oligomeric species of Aβ as detected
by western blot analysis of the material displaced from the tissue.67
This was accompanied by a decrease in Aβ within the tissue section in
the 2 micron oligomer-enriched halo surrounding plaques. While we
cannot rule out compound-mediated displacement of oligomers from
extrasynaptic sites that are below the level of detection of our imaging
methods, oligomers that are dose-dependently displaced by CT1812
are highly likely to originate from synaptic receptor sites; because
oligomers are water-soluble, oligomers in the interstitial fluid in these
frozen tissue sections should freely diffuse in any aqueous media and
be detectable in the vehicle treated condition as well (Figure 3C-E).
The transgenic mouse MIE measurements provide additional insight
on the selectivity of CT1812’s effect on oligomers: a single dose of
CT1812 rapidly increased concentrations of Aβ oligomer, but not
Aβ monomer in the brain. Together, these results demonstrate that
CT1812 is a dose-dependent, negative allosteric modulator of Aβ
oligomer binding.
Unexpectedly, these same measurements provided evidence sug-
gesting that CT1812 directly or indirectly facilitates clearance of Aβ
oligomer, but not monomer, out of the brain and into the CSF; it
rapidly increases ISF and CSF concentrations of oligomers in a dose-
dependentmanner, but notmonomers. The difference in kinetic rate of
increase in Aβ oligomer concentration between the hippocampus and
lateral ventricle may result from different electrode sampling volumes
due to diffusion constraints within brain tissue compared to CSF. The
basis for this selective clearance of Aβ oligomers but not monomers
is currently unclear. While mechanisms of Aβ monomer clearance
from the brain into CSF have been studied extensively (reviewed in
Yuedeet al.40), oligomer clearancemechanismsare currently unknown.
One possible mechanism is suggested by recent studies demonstrat-
ing direct interactions of sigma-2 receptor complex component pro-
teinsPGRMC1andTMEM97with low-density lipoprotein (LDL) recep-
tor, required for ligand-bound LDL receptor internalization,31 and
sigma-2 receptor-mediated cellular uptake of Aβ via interactions with
apolipoprotein E and the LDL receptor.31,68 Previously tested closely
related sigma-2 receptor antagonists do not impact monomer or fibril
levels in Thy1 huAPPSwe/Lnd+ transgenic mice after chronic short-term
administration.26 Tomore fully explore the role of these proteins inAD,
future studies (including studies in AD mouse models cross-bred with
conditional tissue-specific knockouts of each protein to avoid lethality)
are required.
We hypothesize that displacement of toxic Aβ oligomers from
synaptic receptor sites and clearance of oligomer into the CSF under-
lies the improvement of cognitive performance in transgenic AD mice
seenwith chronicCT1812administration.Aswithother closely related
sigma-2 receptor antagonists,26 CT1812 improves transgenic mouse
behavior at brain concentrations corresponding to an estimated 80%
receptor occupancy; typical for an antagonist mechanism of action,
threshold concentrations of drug are required to block effects. While
CT1812’s in vitro assay EC50 values range from high nanomolar to
low micromolar concentrations, behavioral improvement is observed
at brain concentrations closer to CT1812’s Ki at sigma-2 receptors
(8.5 nM). The basis for this difference is unclear but may be due to
the short duration and high concentrations of synthetic Aβ oligomers
used in the in vitro assays. Once displaced from synaptic receptors, the
oligomers are no longer able to harm synapses and are subject to elim-
ination through yet to be defined clearance pathways.
3.2 Preliminary biomarker evidence for CT1812
target engagement and disease-modification in
patients with AD
Protein measurements of CSF samples from the 28-day clinical trial
COG0102 provide preliminary evidence of target engagement and
potential impact on disease in mild-to-moderate AD patients con-
sistent with preclinical data. CSF concentrations of Aβ oligomers
increase in CT1812-treated patients versus placebo similar to pre-
clinical studies, indicating that CT1812 displaces and clears toxic Aβ
oligomer from the brain into CSF. CSF concentrations of the postsy-
naptic dendritic protein neurogranin, typically significantly elevated
in AD patients,51,69–71 are reduced by CT1812 treatment, compared
to changes in placebo patients. Additionally, several synaptic proteins
are significantly different in CT1812- versus placebo-treated patients;
bioinformatics analysis of these changes support preclinical evidence
of a positive impact of CT1812 on synaptic pathways.
Analysis of CSF concentrations of phosphorylated tau fragments in
AD patients revealed that treatment with CT1812 induced a broad
reduction in tau phosphorylation at multiple amino acid sites without
affecting unphosphorylated tau concentration. Many of the residues
altered by CT1812 treatment have been previously implicated in AD-
related changes.72–77 Data correlating phosphorylation at any given
amino acid of tau with disease progression in patients (as well as
how closely mouse disease models reflect such changes) are still
emerging.
Preclinical evidence demonstrates that Aβ oligomer binding results
in upregulation of tau kinase activity2 leading to tau phosphoryla-
tion at multiple sites. The observed reduction in GSK3β as well as tau
phosphorylation in CT1812-treated patients provides the first clinical
biomarker evidence supporting the Aβ oligomer hypothesis of AD and
further support of CT1812’s disease-modifyingmechanism of action.
We hypothesize that changes in CSF concentration of a subset of
proteins with CT1812 treatment reflect target engagement in the
brain. Further clinical studies with longer treatment duration are
underway; treatment-related impact on biomarkers in these indepen-
dent clinical cohorts will provide additional insight on CT1812 target
engagement and AD pathobiology as well as insight into how covari-
ates like sex, age, and apolipoprotein E status impact response to drug.
The effects of these changes in CSF protein concentrations on cogni-
tion and health is unknown and the relative benefit of these effects
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F IGURE 6 Hypothesizedmechanism of action of CT1812: synaptoprotective displacement of toxic amyloid beta (Aβ) oligomers from neurons.
A, In the absence of Aβ oligomers, pre- and post-synaptic proteins such as synaptotagmin-1 and neurogranin are expressed at normal levels. B, The
sigma-2 receptor complex tightly regulates the oligomer receptor complex by stabilizing plasmamembrane expression of oligomer receptor
component proteins. C, Oligomer binding results in changing expression/localization of synapse associated proteins, spine loss, andmemory
failure, as well as upregulation of the sigma-2 receptor complex. D, Fragmented pre- and post-synaptic proteins such as synaptotagmin-1 and
neurograninmove into interstitial fluid and then cerebrospinal fluid. E, CT1812 binds to the sigma-2 receptor ligand binding site within the
sigma-2 receptor complex, acting as a negative allosteric modulator of Aβ oligomer binding. This destabilizes the oligomer binding site and
displaces oligomers from synapses without affecting normal synapse protein function. F, Synapse number andmemory are restored to normal
levels
compared to the risks of the drug are being determined in ongoing and
future placebo-controlled clinical trials.
3.3 CT1812 for the treatment of AD
The hypothesized disease-modifying mechanism of action of CT1812
is illustrated in Figure 6. In the normal brain (Figure 6A), the
sigma-2 receptor complex regulates the plasma membrane surface
expression of putative Aβ oligomer receptor complex component pro-
teins LilRB2, Nogo receptor, and cellular prion protein as well as
several other receptors78 (Figure 6B). In AD, Aβ oligomers bind to
their receptor, altering its function and/or protein interactions, and
resulting in a compensatory upregulation of the sigma-2 receptor
complex (Figure 6C).79,80 The binding of Aβ oligomers then leads to
synaptic damage and release of presynaptic and postsynaptic pro-
teins such as neurogranin and synaptotagmin-1 into the ISF and CSF
(Figure 6D). CT1812 binds to and allosterically modulates the sigma-
2 receptor (Figure 6E), causing destabilization of the neighboring Aβ
oligomer receptor binding sites with resultant displacement of Aβ
oligomers from synaptic receptors (i.e., increase in the “off rate”) with-
out affecting normal synaptic protein function. CT1812 is thus a neg-
ative allosteric modulator of Aβ oligomer binding to synaptic recep-
tors. As a result of the removal of toxic oligomers, synapse number and
memory are restored to normal (Figure 6F). CT1812 selectively dis-
places Aβ oligomers shortly after entering the brain and prevents them
from rebinding as long as brain drug levels remain above an estimated
80% receptor occupancy.26 Chronic administration provides sustained
protection from the synaptotoxic oligomer assault, facilitating synaptic
recovery.
The current studies suggest that CT1812 effectively and selec-
tively targets Aβ oligomers by a novel mechanism of action not
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previously demonstrated for any other therapeutics currently in devel-
opment. CT1812 is both the first selective sigma-2 receptor antag-
onist to be used in clinical trials, and the first therapeutic demon-
strated to displace toxic Aβ oligomers from synaptic receptor sites
and selectively facilitate their clearance into the CSF. Displacement
of oligomers lowers their binding affinity (KD) to synaptic receptors
significantly, thus CT1812 is the only therapeutic currently in devel-
opment that mimics the effect of the protective Icelandic A673T
mutation.6 This mechanism is significant, as therapeutics that recapit-
ulate the effects of protective mutations have a track record of clinical
success.66
Currently, approvedADmedications do not stop the disease course,
but simply treat symptoms for a limited time. These preclinical results
of CT1812 in rodent models of AD demonstrate that CT1812 blocks
Aβ oligomer binding to neurons, reduces synapse loss, restores synap-
tic protein expression, facilitates oligomer clearance into the CSF, and
restores cognitive function. The ability of CT1812 to improve cognitive
performance in transgenic mice while not affecting the performance
of WT mice supports a specific effect of CT1812 on the pathologi-
cal pathway of AD: this disease-selective mechanism may provide an
advantage over other therapeutic approaches that impact brain func-
tionmore widely.
Preliminary evidence from the phase 1b/2a clinical trial reported
here supports these findings. This study was limited by small patient
numbers and short duration of treatment in the COG0102 trial. Larger
studies with additional dose levels will be required to establish dose–
response relationships with biomarker changes, and distinguish both
acute and long-term disease-modifying effects of CT1812 treatment.
While not all proteins and signaling pathways known to be dysregu-
lated inADwere affectedby treatmentwithCT1812, several pathways
were significantly impacted (including cholesterol transport, oxidative
stress, complement, and synaptic transmission; Figure 5E). Together,
these results provide encouraging evidence of the impact of CT1812
onmultiple aspectsof disease inADpatients and support furtherdevel-
opment of this drug candidate so that the relative benefit and risks of
CT1812 can bemore thoroughly evaluated.
CT1812 is currently being studied in four randomized, double-
blind, placebo-controlled phase 2 studies (6 months–1 year in
treatment duration) in patients with mild to moderate AD: SNAP
(NCT03522129), SPARC (NCT03493282), SHINE (NCT03507790),
and SEQUEL. An additional 18-month study in 540 early AD patients
(MMSE 20–30) is being planned in collaborationwith the ACTC clinical
trial network. The safety and tolerability of CT1812will continue to be
explored in all clinical trials.
4 MATERIALS AND METHODS
4.1 Radioligand binding
Radioligand competition assays to determine affinity for sigma-2
and sigma-1 receptors were performed at Eurofins Cerep SA (Le
Bois L’évêque, France) in membranes from Jurkat cells (immortalized
human T cells). Assays for sigma-2 receptors used 25 nM [3H]1,3-
di(2-tolyl) guanidine in the presence of 1 μM (+)-pentazocine while
assays for sigma-1 receptors used 15 nM [3H](+)-pentazocine. Non-
specific binding in both assays was defined in the presence of 10
μM haloperidol.81 Estimated percent receptor occupancy for in vivo
behavioral studies (see below) was calculated according to the formula
100*(concentration/Ki)/([concentration/Ki] + 1), where Ki is deter-
mined by radioligand competition binding (CT1812= 8.5 nM).26
4.2 Neuronal cultures
Mixed neuronal and glia cultures were made from embryonic day 18
(E18) Sprague Dawley rat brains and grown in poly-D Lysine coated
plates for 21 days, as previously described.26,28 All procedures were
approved by the Institutional Animal Care and Use Committee at Cog-
nition Therapeutics and were in compliance with the Office of Labora-
tory Animals Welfare and the Guide for the Care and Use of Labora-
tory Animals, Eighth Edition. Embryos from a single rat were pooled to
produce a unique dissociated neuronal culture. All analyses described
below were performed on at least three unique cultures. Healthy cul-
tures typically contain 20% to 35% MAP2-positive neurons. CT1812
was tested in quadruplicate wells for each concentration in at least
three replicate experiments with data from all experiments pooled for
analysis with means± standard deviation (SD) or standard error of the
mean (SEM) as noted.
4.3 Aβ oligomer preparation
Synthetic human Aβ1-42 peptide was prepared as previously
described.26,28 Briefly, peptide was treated according to published
methods to remove any structural assemblies.82,83 An Aβ monomer
film was prepared, dissolved, diluted to 100 μM, and incubated at 4◦C
to form oligomers. The resulting preparations were centrifuged to
remove any insoluble fibrils, and the supernate added to cultures. All
studies using synthetic oligomers were performed with this prepa-
ration unless otherwise specified. All lots of Aβ1-42 are put through
a strict quality control processes, described previously,26,28 before
use in experiments. As previously reported, oligomers produced via
this method typically range from 25–275 kDa when measured via
non-denatured western blots (Figure 226).
Human AD patient- (Braak V/VI) and age-matched control hip-
pocampal brain specimens, less than 24 hours post mortem, were
obtained from the Brown Brain Bank following previously described
procedures.26,28 Tissue was prepared as previously described.26,28
Briefly, the brain tissue was homogenized and centrifuged, super-
nate were immuno-depleted and concentrated to obtain the 10–
100 kDa size-fractionated oligomers, which were then captured on
6E10-conjugated agarose columns (Pierce). The released material was
desalted and stored at –80◦C. Use of post mortem brain specimens met
the exemption criteria for Department of Health and Human Services
regulations, as previously explained.26,28
IZZO ET AL. 13
4.4 In vitro trafficking assay
Vesicular trafficking was measured using an adaptation of a method
as previously described.26,84 Neurons were treated with compounds
and/or Aβ oligomer preparations (0.086%DMSO in culturemedia) and
incubated for 1 to 24 hours at 37◦C in 5%CO2. For prevention studies,
CT1812was addedat indicated concentrations 1hour prior to addition
of Aβ oligomers. In treatment studies, Aβ oligomers were added 1 hour
prior to addition of CT1812. Tetrazolium salts (3-[4,5-dimethylthiazol-
2yl]-2,5diphenyl tetrazolium bromide, Roche Molecular Biochemicals)
were added at a final concentration of 0.75mM and incubated at 37◦C
for 60 to 90 minutes. Vesicular formazan remaining in cells was quan-
tified by absorbance spectrometry (590 nm with 690 nm subtracted)
after extraction with 1.6% Tween-20. All compounds were tested in
quadruplicate wells for each concentration in at least eight replicate
experiments with data from all experiments pooled for analysis with
means± SEM.
4.5 In vitro Aβ binding assay
Assessment of Aβ oligomer binding was performed as previously
described.26,28 Briefly, cultures were either (for prevention studies)
treated with CT1812 for 30 minutes, followed by synthetic Aβ1-42
oligomer preparation for 60 minutes, or (for displacement studies)
treated with oligomers 30 minutes prior to the addition of CT1812.
Cells were then fixed and labeled for immunofluorescent microscopy
as previously described.26 All data forAβbinding presented represents
total fluorescent intensity of Aβ label in neurite spots per neuron in rel-
ative fluorescent units (RFUs). Replications and statistical procedures
for the quantification of Aβ immunofluorescent intensity were previ-
ously described.26
4.6 In vitro synapse counting assay
Synapse number was quantified using quantitative immunofluores-
centmicroscopy of drebrin-labeled puncta (Millipore AB-10140) along
MAP2-positive neurites (Millipore AB5543) as previously described.26
Additional immunofluorescent labeling was performed on neuronal
cultures for SYT-1 (Synaptic Systems #105 103) and for neurogranin
(Abcam ab23570).
4.7 Human tissue ex vivo Aβ displacement
Displacement of Aβ from human tissue was assessed as previously
described.28 Briefly, brains from human AD patients were obtained
through the Massachusetts Alzheimer’s Disease Research Center and
Massachusetts General Hospital (MGH) Neuropathology Department.
Experiments using human brain were reviewed and approved by the
Academic and Clinical Central Office for Research and Development
medical research ethics committee, a joint office of the University of
Edinburgh and National Health Service (NHS) Lothian (approval 15-
HV-016). Parahippocampal gyrus sections (one section per specimen
per condition) were incubated with 0.1, 1.0, 10, or 15 μM CT1812 in
phosphate-buffered saline (PBS), or vehicle for 60 minutes as previ-
ously described26 and then labeled with an antibody specific to Aβ
(AW-7, gift from Dominic Walsh85). Dense core amyloid plaques and
NFTs were labeled with 0.05% Thioflavin-S (Sigma Aldrich) in 50%
ethanol for 8 minutes before treatment with 80% ethanol for 30
seconds. Images were analyzed in ImageJ86 using a custom macro
(described in figure S4 in Izzo et al.28). A total of 105 to 279 plaques
were analyzed for each treatment from eight different donors and
average intensities for each specimen were calculated. The median
intensity valuewas calculated for each specimen and subjected tomul-
tivariate correlation analysis as previously described.28 Determination
of total Aβ concentration eluted from human donor brain tissue was
performed using a high sensitivity, human Beta Amyloid (1-42) ELISA
Kit (Wako, cat # 296-64401) which uses BAN50/BC05 (Fab’).
4.8 Western blot analysis of Aβ oligomers
Non-denaturing western blot conditions were used to avoid the
generation of Aβ assembly and disassembly artifacts, as previously
described.26 Briefly, baseline and end of study CSF samples from
AD patients participating in clinical trial COG0102 were collected in
polypropylene tubes in 500 μL and frozen at –80◦C until analysis.
Upon receipt, the samples were thawed and quickly aliquoted into
polypropylene tubes coated with isotonic human serum albumin and
refrozen until analysis by native western gels. Because the effects
of blood on Aβ oligomer formation in CSF is unknown, an aliquot of
each patient sample was pre-analyzed on a western blot using lumi-
nol and horseradish peroxide to test for the presence of heme. Final
western gel analysis was performed on samples excluding those con-
taining hemolyzed blood. Samples were run on Tris-HCl nondenatur-
ing gels, transferred to nitrocellulose, and probed with 82E1 mouse
monoclonal Aβ antibody (IBL America) and visualized by chemilumi-
nescence after detection using a goat anti mouse IgG-horseradish
peroxidase secondary antibody (Millipore). All reagents were filtered
through 0.1 micron filters to eliminate background debris. Band inten-
sities on the gels were quantified using an Alpha Innotech image sys-
tem and Alpha View software (ProteinSimple). Each patient’s sample
at day 28 was normalized as a percent of that patient’s own baseline
value.
4.9 Measurement of Aβ using
microimmunoelectrodes
APP/PS1+/− hemizygous mice42 were bred to WT C3H/B6 mice (The
Jackson Laboratory) and the APP/PS1+/− offspring were used for
experiments at 12 months of age. Male and female littermate mice
were distributed between experimental groups.
MIEs, which can measure Aβ every 60 seconds for up to 3 hours,
were prepared similar to previously described methods.40 Carbon
fiber microelectrodes were used as the platform sensor due to their
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high signal-to-noise ratio, biological compatibility, andminiature size,87
and ability to sensitively detect tyrosine oxidation (66). Electrodes
were coated with antibodies specific for Aβ monomer (HJ2)40 or for
oligomers (A11)41 and inserted into the hippocampus tomeasure brain
ISF Aβ levels or into lateral ventricles tomeasure CSF Aβ levels.
Electrodes were pre-calibrated in vitro (see supporting informa-
tion). In addition to the MIE, a stainless-steel bone screw used as a
counter electrode andanAg/AgCl reference electrode (InVivoMetrics)
were implanted into the brains of 12-month-old APP/PS1+/- trans-
genic mice. All electrodes were stereotaxically implanted under isoflu-
orane anesthesia. Mice were placed on a heating pad to maintain body
temperature and repetitive SWV scans were run every 60 seconds for
up to 180minutes using a CH Instruments 830D Electrochemical Ana-
lyzer with PicoAmp booster. The stereotax was enclosed in a faraday
cage to reduce electrical noise. CT1812 or vehicle were administered
intravenously via tail vein injectionat the concentrationsnoted.All pro-
cedures were approved by the Institutional Animal Care andUse Com-
mittee atWashingtonUniversity, St. Louis, andwere in compliancewith
the Office of Laboratory Animals Welfare and the Guide for the Care
and Use of Laboratory Animals, Eighth Edition.
More detail can be found in the supporting information section.
4.10 Behavioral studies
All procedures were approved by the Institutional Animal Care and
Use Committee at Stanford University and were in compliance with
the Office of Laboratory Animal Welfare and the Guide for the Care
and Use of Laboratory Animals, Eighth Edition. Testing of male trans-
genic Thy1 huAPPSwe/Lnd+ mice in the Morris water maze, Y-Maze, or
fear conditioning tasks was done according to publishedmethods.45,46
Studiesweredesignedwith four arms:WT, vehicle treated (n=12);WT,
CT1812 treated (n = 12); transgenic, vehicle treated (n = 12); trans-
genic, CT1812 treated (n = 13). All procedures were approved by the
Institutional Animal Care and Use Committee at Stanford University
andwere in compliancewith theOffice of Laboratory AnimalsWelfare
and the Guide for the Care and Use of Laboratory Animals, Eighth Edi-
tion.
To measure brain concentration of drugs, brains were homogenized
in 1 mL PBS per gram of brain tissue using a handheld homogenizer.
Brain homogenate was then extracted with three volumes of ice-cold
methanol on ice for 15 minutes and centrifuged for 15 minutes. The
supernates were analyzed by LC-MS/MS. Samples were compared to
a calibration curve prepared in a similar manner by spiking blank con-
trol homogenatewith standards prepared inDMSOand then extracted
as above.
4.11 Clinical trial of CT1812 in mild-to-moderate
AD patients
The clinical trial was performed at six sites in Australia and admin-
istered by Neuroscience Trials Australia. The study protocol was
approved by theHumanResearch Ethics Committee at the AlfredHos-
pital, Melbourne, Australia, and was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. All sub-
jects provided written informed consent before participating. Mild to
moderate (MMSE18–26)ADpatients (N=19)were randomized toone
of three doses of CT1812 (90, 280, or 560 mg Q.D.) or placebo given
orally once daily for 28 days (4 weeks) to determine safety and toler-
ability (COG0102, for full listing of inclusion and exclusion criteria see
ClinicalTrials.govNCT02907567). Exploratory outcomes includedCSF
protein expression measured at baseline (Day 0) and end of treatment
(Day 28). Missing samples (declined or failed spinal taps) and variable
CSF sample volumes reduced the number of matched baseline and day
28 patient CSF samples available for subsequent analysis.
4.12 ELISA measurement of CSF synaptic
proteins
CSF levels of Aβ40, Aβ42, t-tau, and p-tau were measured using
the INNOTEST ELISA (Fujirebio, Ghent, Belgium), following the rec-
ommendations by the manufacturer. NfL was measured using an
ELISA from Uhman Diagnostics. These analyses were conducted by
board-certified laboratory technicians according to Swedish Board
for Accreditation and Conformity Assessment (SWEDAC)-approved
protocols. Neurogranin CSF concentrations were measured using an
in-house ELISA method based on the Ng2 and Ng22 antibodies, as
described previously in detail.88 Concentrations of SNAP-25 in CSF
were measured using immunoprecipitation combined with mass spec-
trometry (IP-MS) as described previously.89
4.13 LC-MS/MS measurement of CSF synaptic
proteins and phosphorylated tau fragments
Synaptotagmin-1measurementswereobtainedaspart of unbiasedLC-
MS/MS proteomics analysis of AD patient CSF samples at Caprion Bio-
sciences using published methods.90 Additional unbiased proteomics
analyses including an enrichment for phospho-proteome were per-
formed on CSF samples at Proteome Sciences using the protocols as
previously published61,91 withminormodifications. For statistical anal-
ysis of unbiased LC-MS-MSproteomics, a linearmixedmodelwas used.
Detailedmethods can be found in the supporting information section.
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